271 results on '"Berton-Rigaud, Dominique"'
Search Results
2. Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from the randomized phase II trial CHIVA (GINECO).
3. Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under neoadjuvant chemotherapy
4. Management of Rare Uterine Malignant Tumors
5. Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)
6. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
7. “Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors”
8. Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028
9. Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial
10. #208 Metabolic syndrome, long-term fatigue and inflammation in epithelial ovarian cancer survivors: vivrovaire, ancillary study
11. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
12. Ovarian Cancer and HIPEC: In the Era of Evidence Based Medicine
13. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)
14. Figure S8 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
15. Supplementary Table 3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
16. FIGURE 3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
17. FIGURE 2 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
18. FIGURE 4 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
19. FIGURE 1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
20. Data from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
21. Supplementary Table 2 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
22. Supplementary Table 1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
23. Dissecting the origin of heterogeneity in uterine and ovarian carcinosarcomas
24. Management of Rare Uterine Malignant Tumors
25. supplementary table 2 from PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients
26. supplementary table 4 from PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients
27. supplementary table 1 from PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients
28. supplementary table 3 from PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients
29. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
30. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study
31. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer
32. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
33. Ovarian Cancer and HIPEC: In the Era of Evidence Based Medicine
34. Surgical Implications of Advanced Low-Grade Serous Ovarian Cancer: Analysis of the Database of the Tumeurs Malignes Rares Gynécologiques Network
35. Survival Benefit of Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer: A Multi-institutional Case Control Study
36. Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study
37. EARLY DEATH IN ADVANCED OVARIAN CANCER IN OLDER ADULTS
38. 268 A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101)
39. New systemic therapy for breast cancer
40. Oxaliplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Primary or Recurrent Epithelial Ovarian Cancer: A Pilot Study of 31 Patients
41. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
42. Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography
43. Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node-positive, early-stage, invasive breast carcinoma undergoing breast-conserving surgery: Results of the French Adjuvant Study Group
44. Pertuzumab for the treatment of breast cancer
45. Pooled analysis of onapristone extended release (ONA ER) in metastatic cancer patients (pts): A review of liver safety.
46. Menopausal symptoms in epithelial ovarian cancer survivors: The GINECO VIVROVAIRE2 study.
47. Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer
48. Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers
49. Pertuzumab for the treatment of breast cancer.
50. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.